Dr Scott Smid
Senior Lecturer
School of Pharmacy and Biomedical Sciences
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. Current interests include novel ligand development for binding and inhibiting pathological aggregating proteins such as beta-amyloid and alpha-synuclein, which are associated with Alzheimer's and Parkinson's disease.
Current projects for Masters, M.Phil or PhD candidates include:
1. Identifying novel cannabis phytochemicals with neuroprotective properties. This includes using neural stem cells and other neuronal cell populations to model neurotoxicity to dementia-associated misfolding proteins such as amyloid beta and alpha-synuclein, related to Alzheimer's and Parkinson's disease. We have identified a range of cannabis phytochemicals with bioactive properties, including novel phytocannabinoids, selected terpenes and a novel cannabis flavonoids with neuroprotective activity that could be used in nutritional or nutraceutical settings in ageing.
2. Identifying and characterising novel cannabis phytochemicals and derivatives with chemotherapeutic properties, including antibiotic bioactivity. The non-psychotropic component of cannabis, cannabidiol (CBD) and its derivatives have bacteriostatic and bacteriocidal activity against a range of Gram-positive bacteria, but also has been shown to arrest cell growth and division in human malignant cell lines via undefined mechanisms. This may enable further use of CBD and derivatives as adjunctive or standalone treatments in cancer.
3. Identifying and characterising diverse and novel natural products and constituent polyphenols with gastro- and neuro-protective properties, including intestinal barrier function and antimicrobial activity. This includes recent and previous research including international collaborations using seaweeds, grape skin, tea, acai and Goji berry to name a few.
| Date | Position | Institution name |
|---|---|---|
| 2015 - ongoing | Visiting Fellow | University of Western Australia, Perth |
| 2012 - ongoing | Deputy Head | University of Adelaide, Adelaide |
| 2006 - ongoing | Senior Lecturer | University of Adelaide, Adelaide |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2012 | Award | Faculty International Conference Award (FICA) | - | - | - |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 1991 - 1994 | University of Adelaide, Adelaide | Australia | Doctor of Philosophy |
| 1990 | University of Adelaide, Adelaide | Australia | Honours Degree of Bachelor of Science (Class 1 Honours) |
| 1979 - 1989 | University of Adelaide, Adelaide | Australia | Bachelor of Science |
| Year | Citation |
|---|---|
| 2025 | Bellas, O. M., Cao, K., Bowen, J., Smid, S., Shakib, S., Crawford, G. B., . . . Wardill, H. R. (2025). Medicinal CANnabis (CBD/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial. BMJ Open, 15(3), e089336-1-e089336-10. Scopus1 Europe PMC1 |
| 2025 | Kamonsuwan, K., Kaewpradup, T., Chusak, C., Charoensiddhi, S., Smid, S., & Adisakwattana, S. (2025). β-Glucosidase-pretreated black goji berry tea reduces glucose release and enhances bile acid binding co-digestion with high-fat meals in simulated digestion. Scientific Reports, 15(1), 12484. |
| 2025 | Charoensiddhi, S., Kato, R., Zhang, W., & Smid, S. (2025). Duckweed (Wolffia globosa) improves intestinal epithelial barrier function induced by gut microbial metabolites in vitro. Food Chemistry Advances, 9, 101157. |
| 2024 | Kamonsuwan, K., Balmori, V., Marnpae, M., Chusak, C., Thilavech, T., Charoensiddhi, S., . . . Adisakwattana, S. (2024). Black Goji Berry (Lycium ruthenicum) Juice Fermented with Lactobacillus rhamnosus GG Enhances Inhibitory Activity against Dipeptidyl Peptidase-IV and Key Steps of Lipid Digestion and Absorption.. Antioxidants (Basel), 13(6), 20 pages. Scopus12 WoS12 Europe PMC6 |
| 2024 | Marsh, D. T., & Smid, S. D. (2024). Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.. Toxicol In Vitro, 99, 105888. Scopus2 WoS2 Europe PMC2 |
| 2024 | Marsh, D. T., Shibuta, M., Kato, R., & Smid, S. D. (2024). Medicinal cannabis extracts are neuroprotective against Aβ1-42-mediated toxicity in vitro.. Basic Clin Pharmacol Toxicol, 135(5), 575-592. Scopus3 WoS2 Europe PMC2 |
| 2024 | Staton Laws Iii, J., & Smid, S. D. (2024). Sesquiterpene-evoked phytochemical toxicity in PC12 neuronal cells reveals a variable degree of oxidative stress and alpha-tocopherol and glutathione-dependent protection.. Curr Res Toxicol, 6, 100144. Scopus5 WoS6 Europe PMC3 |
| 2023 | Marsh, D. T., Sugiyama, A., Imai, Y., Kato, R., & Smid, S. D. (2023). The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β‐evoked neurotoxicity and changes in cell morphology in PC12 cells. Basic & Clinical Pharmacology & Toxicology, 134(3), 293-309. Scopus10 WoS11 Europe PMC9 |
| 2023 | Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30. Scopus4 WoS3 Europe PMC4 |
| 2023 | Laws, J. S., & Smid, S. D. (2023). Characterizing cannabis-prevalent terpenes for neuroprotection reveal a role for α and β-pinenes in mitigating amyloid β-evoked neurotoxicity and aggregation in vitro.. Neurotoxicology, 100, 16-24. Scopus8 WoS7 Europe PMC3 |
| 2022 | Laws III, J. S., Shrestha, S., & Smid, S. D. (2022). Cannabis terpenes display variable protective and anti-aggregatory actions against neurotoxic β amyloid in vitro: highlighting the protective bioactivity of α-bisabolol in motorneuronal-like NSC-34 cells. NeuroToxicology, 90, 81-87. Scopus11 WoS10 Europe PMC4 |
| 2022 | Shrestha, S., Choi, J. S., Zhang, W., & Smid, S. D. (2022). Neuroprotective activity of macroalgal fucofuroeckols against amyloid β peptide-induced cell death and oxidative stress. International Journal of Food Science and Technology, 57(7), 4286-4295. Scopus6 WoS4 |
| 2022 | Marsh, D. T., & Smid, S. D. (2022). The semi-synthetic flavonoid 2',3',4'-trihydroxyflavone (2-D08) inhibits both SN-38- and cytokine-evoked increases in epithelial barrier permeability in an in vitro intestinal mucositis model.. Food Funct, 13(21), 11142-11152. Scopus2 WoS1 Europe PMC1 |
| 2022 | Laws III, J., & Smid, S. D. (2022). Evaluating Cannabis sativa L.'s neuroprotection potential: From bench to bedside.. Phytomedicine, 107, 1-12. Scopus13 WoS15 Europe PMC6 |
| 2021 | Shrestha, S., Zhang, W., & Smid, S. D. (2021). Phlorotannins: A review on biosynthesis, chemistry and bioactivity. Food Bioscience, 39, 100832-1-100832-11. Scopus126 WoS112 |
| 2021 | Shrestha, S., Johnston, M. R., Zhang, W., & Smid, S. D. (2021). A phlorotannin isolated from Ecklonia radiata, Dibenzodioxin-fucodiphloroethol, inhibits neurotoxicity and aggregation of β-amyloid. Phytomedicine Plus, 1(4), 100125-1-100125-9. Scopus19 |
| 2021 | Dos Reis Franco, G., Smid, S., & Viegas, C. (2021). Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases.. Current neuropharmacology, 19(4), 449-464. Scopus35 WoS29 Europe PMC20 |
| 2020 | Marsh, D. T., & Smid, S. D. (2020). Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents. AUSTRALIAN JOURNAL OF CHEMISTRY, 74(6), 388-404. Scopus16 WoS15 |
| 2020 | Jovcevski, B., Das, S., Smid, S., & Pukala, T. L. (2020). Polyphenol honokiol and flavone 2′,3′,4′-trihydroxyflavone differentially interact with α-synuclein at distinct phases of aggregation. ACS Chemical Neuroscience, 11(24), 4469-4477. Scopus18 WoS15 Europe PMC11 |
| 2020 | Gunasegaran, B., Neilsen, P. M., & Smid, S. D. (2020). P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.. Toxicol In Vitro, 67, 104908. Scopus4 WoS3 Europe PMC3 |
| 2020 | Shrestha, S., Zhang, W., Begbie, A. J., Pukala, T. L., & Smid, S. D. (2020). Ecklonia radiata extract containing eckol protects neuronal cells against Aβ1-42 evoked toxicity and reduces aggregate density.. Food Funct, 11(7), 6509-6516. Scopus17 WoS14 Europe PMC7 |
| 2020 | Alghazwi, M., Charoensiddhi, S., Smid, S., & Zhang, W. (2020). Impact of Ecklonia radiata extracts on the neuroprotective activities against amyloid beta (Aβ<inf>1-42</inf>) toxicity and aggregation. Journal of Functional Foods, 68, 9 pages. Scopus28 WoS24 |
| 2019 | Eggers, C., Fujitani, M., Kato, R., & Smid, S. (2019). Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone.. Biochemical pharmacology, 169, 113609. Scopus51 WoS40 Europe PMC33 |
| 2019 | Das, S., & Smid, S. D. (2019). Small molecule diketone flavorants diacetyl and 2,3-pentanedione promote neurotoxicity but inhibit amyloid β aggregation. Toxicology Letters, 300, 67-72. Scopus10 WoS9 Europe PMC4 |
| 2019 | Alghazwi, M., Smid, S., Karpiniec, S., & Zhang, W. (2019). Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida. International Journal of Biological Macromolecules, 122, 255-264. Scopus49 WoS39 Europe PMC30 |
| 2019 | Alghazwi, M., Smid, S., Musgrave, I., & Zhang, W. (2019). In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ₁−₄₂) toxicity and aggregation. Neurochemistry International, 124, 215-224. Scopus96 WoS89 Europe PMC69 |
| 2019 | Li, X., Smid, S. D., Lin, J., Gong, Z., Chen, S., You, F., . . . Jin, X. (2019). Neuroprotective and anti-amyloid β effect and main chemical profiles of white tea: Comparison against green, oolong and Black tea. Molecules, 24(10), 1-15. Scopus41 WoS29 Europe PMC18 |
| 2018 | Alghazwi, M., Smid, S., & Zhang, W. (2018). In vitro protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (Aβ₁−₄₂) induced neurotoxicity in PC-12 cells. Neurotoxicology and Teratology, 68, 72-83. Scopus8 WoS8 Europe PMC4 |
| 2018 | Das, S., Pukala, T., & Smid, S. (2018). Exploring the structural diversity in inhibitors of α-Synuclein amyloidogenic folding, aggregation, and neurotoxicity. Frontiers in Chemistry, 6(MAY), 181-1-181-12. Scopus25 WoS27 Europe PMC16 |
| 2018 | Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15. Scopus15 WoS14 Europe PMC12 |
| 2017 | Das, S., & Smid, S. (2017). Identification of dibenzyl imidazolidine and triazole acetamide derivatives through virtual screening targeting amyloid beta aggregation and neurotoxicity in PC12 cells. European Journal of Medicinal Chemistry, 130, 354-364. Scopus19 WoS18 Europe PMC13 |
| 2017 | Marsh, D., Das, S., Ridell, J., & Smid, S. (2017). Structure-activity relationships for flavone interactions with amyloid β reveal a novel anti-aggregatory and neuroprotective effect of 2′,3′,4′-trihydroxyflavone (2-D08). Bioorganic and Medicinal Chemistry, 25(14), 3827-3834. Scopus38 WoS36 Europe PMC19 |
| 2017 | Campaniello, M. A., Mavrangelos, C., Eade, S., Harrington, A. M., Blackshaw, L. A., Brierley, S. M., . . . Hughes, P. A. (2017). Acute colitis chronically alters immune infiltration mechanisms and sensory neuro-immune interactions.. Brain, Behavior, and Immunity, 60, 319-332. Scopus19 WoS17 Europe PMC14 |
| 2016 | Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258. Scopus23 WoS22 Europe PMC16 |
| 2016 | Das, S., Stark, L., Musgrave, I., Pukala, T., & Smid, S. (2016). Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity. Food & Function, 7(2), 1138-1146. Scopus50 WoS45 Europe PMC28 |
| 2016 | Safdari, B., Sia, T., Wattchow, D., & Smid, S. (2016). Effects of pro-inflammatory cytokines, lipopolysaccharide and COX-2 mediators on human colonic neuromuscular function and epithelial permeability. Cytokine, 83, 231-238. Scopus20 WoS15 Europe PMC14 |
| 2016 | Alghazwi, M., Kan, Y., Zhang, W., Gai, W., Garson, M., & Smid, S. (2016). Neuroprotective activities of natural products from marine macroalgae during 1999–2015. Journal of Applied Phycology, 28(6), 3599-3616. Scopus53 WoS46 |
| 2014 | Janefjord, E., Maag, J., Harvey, B., & Smid, S. (2014). Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cellular and Molecular Neurobiology, 34(1), 31-42. Scopus112 WoS98 Europe PMC86 |
| 2014 | Harvey, B., Sia, T., Wattchow, D., & Smid, S. (2014). Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine, 65(2), 236-244. Scopus30 WoS26 Europe PMC22 |
| 2013 | Wong, D., Musgrave, I., Harvey, B., & Smid, S. (2013). Açaí (Euterpe oleraceae Mart.) berry extract exerts neuroprotective effects against β-amyloid exposure in vitro. Neuroscience Letters, 556, 221-226. Scopus50 WoS41 Europe PMC33 |
| 2013 | Harvey, B., Nicotra, L., Vu, M., & Smid, S. (2013). Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine (Online), 63(2), 209-217. Scopus32 WoS29 Europe PMC28 |
| 2013 | Nicotra, L., Vu, M., Harvey, B., & Smid, S. (2013). Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins & Other Lipid Mediators, 100(1), 22-29. Scopus20 WoS19 Europe PMC15 |
| 2012 | Smid, S., Maag, J., & Musgrave, I. (2012). Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical. Food & Function: linking the chemistry and physics of food with health and nutrition, 3(12), 1242-1250. Scopus60 WoS54 Europe PMC34 |
| 2012 | Harvey, B., Ohlsson, K., Maag, J., Musgrave, I., & Smid, S. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1), 138-146. Scopus73 WoS66 Europe PMC51 |
| 2012 | Harvey, B., & Smid, S. (2012). The gastrointestinal endocannabinoid system in health and inflammation. Current Topics in Pharmacology, 16(1), 107-118. Scopus1 |
| 2011 | Harvey, B., Musgrave, I., Ohlsson, K., Fransson, A., & Smid, S. (2011). The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro. Food Chemistry, 129(4), 1729-1736. Scopus42 WoS37 Europe PMC17 |
| 2009 | Smid, S. (2009). Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clinical Ophthalmology (online), 3(1), 663-670. Scopus16 WoS14 Europe PMC10 |
| 2009 | Smid, S., & Svensson, K. (2009). Inhibition of cyclooxygenase-2 and EP₁ receptor antagonism reduces human colonic longitudinal muscle contractility in vitro. Prostaglandins & Other Lipid Mediators, 88(3-4), 117-121. Scopus14 WoS13 Europe PMC13 |
| 2008 | Smid, S. (2008). Gastrointestinal endocannabinoid system: Multifaceted roles in the healthy and inflamed intestine. Clinical and Experimental Pharmacology and Physiology, 35(11), 1383-1387. Scopus16 WoS14 Europe PMC9 |
| 2007 | Smid, S., Bjorklund, C., Svensson, K., Heigis, S., & Revesz, A. (2007). The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. European Journal of Pharmacology, 575(1-3), 168-176. Scopus29 WoS24 Europe PMC19 |
| 2006 | Hinds, N., Ullrich, K., & Smid, S. (2006). Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. British Journal of Pharmacology, 148(2), 191-199. Scopus58 WoS54 Europe PMC52 |
| 2005 | Smith, A., & Smid, S. (2005). Impaired capsaicin and neurokinin-evoked colonic motility in inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 20(5), 697-704. Scopus30 WoS30 Europe PMC28 |
| 2002 | Lehmann, A., Blackshaw, L., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology, 123(4), 1129-1134. Scopus92 WoS66 Europe PMC61 |
| 2002 | Lehmann, A., Blackshaw, L. A., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. D. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (vol 123, pg 1129, 2002). GASTROENTEROLOGY, 123(6), 2162-2163. |
| 2002 | Lehmann, A., Blackshaw, L. A., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. D. (2002). Erratum: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (Gastroenterology (2002) 123 (1129-1134)). Gastroenterology, 123(6), 2162-2163. |
| 2001 | Smid, S., Young, R., Isaacs, N., & Blackshaw, L. (2001). GABABR expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. American Journal of Physiology - Gastrointestinal and Liver Physiology, 281(6), G1494-G1501. Scopus67 WoS50 Europe PMC48 |
| 2001 | Smid, S. D., & Blackshaw, L. A. (2001). GABA<sub>B</sub> receptors inhibit vagal afferent mechanoreceptor responses to gastric distension.. GASTROENTEROLOGY, 120(5), A5-A6. |
| 2000 | Smid, S. D., & Blackshaw, L. A. (2000). Ganglionic and neuroeffector transmission to the ferret lower esophageal sphincter in a novel <i>in vitro</i> oesophagogastric preparation.. GASTROENTEROLOGY, 118(4), A155. |
| 2000 | Blackshaw, L., Smid, S., Dent, J., & O'Donnell, T. (2000). GABAB receptor-mediated effects on vagal pathways to the lower oesophageal sphincter and heart. British Journal of Pharmacology, 130(2), 279-288. Scopus43 WoS35 Europe PMC33 |
| 2000 | Staunton, E., Smid, S., Dent, J., & Blackshaw, L. (2000). Triggering of transient LES relaxations in ferrets: role of sympathetic pathways and effects of baclofen. American Journal of Physiology-Gastrointestinal and Liver Physiology, 279(1 42-1), G157-G162. Scopus46 WoS34 Europe PMC30 |
| 2000 | Blackshaw, L., Page, A., Smid, S., Dent, J., & Lehmann, A. (2000). GABAB receptors - peripheral and central targets for controlling gastroesophageal reflux. Current Opinion in Central & Peripheral Nervous System Investigational Drugs, 2(3), 333-343. Scopus6 |
| 2000 | Smid, S., & Blackshaw, L. (2000). Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus. Gut, 46(6), 756-761. Scopus19 WoS16 Europe PMC12 |
| 2000 | Smid, S., & Blackshaw, L. (2000). Vagal neurotransmission to the ferret lower oesophageal sphincter: inhibition via GABAB receptors. British Journal of Pharmacology, 131(3), 624-630. Scopus26 WoS21 Europe PMC21 |
| 2000 | Smid, S., & Blackshaw, L. (2000). Vagal ganglionic and nonadrenergic noncholinergic neurotransmission to the ferret lower oesophageal sphincter. Autonomic Neuroscience-Basic & Clinical, 86(1-2), 30-36. Scopus6 WoS5 Europe PMC5 |
| 1999 | Blackshaw, L. A., Smid, S. D., Smid, S. D., O'Donnell, T. A., & Dent, J. (1999). GABA<sub>B</sub> receptors inhibit vagal influence on the lower oesophageal sphincter (LOS). GASTROENTEROLOGY, 116(4), A960. WoS4 |
| 1998 | Smid, S. D., Page, A. J., O'Donnell, T., Langman, J., Rowland, R., & Blackshaw, L. A. (1998). Oesophagitis-induced changes in capsaicin-sensitive tachykininergic pathways in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(5), 403-411. Scopus15 WoS11 Europe PMC11 |
| 1998 | Smid, S. D., Lynn, P. A., Templeman, R., & Blackshaw, L. A. (1998). Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(2), 149-156. Scopus17 WoS15 Europe PMC14 |
| 1998 | Smid, S. D., Dent, J., & Blackshaw, L. A. (1998). In vitro function of the human lower esophageal sphincter (LES) in Barrett's esophagus. GASTROENTEROLOGY, 114(4), A289. |
| 1997 | Smid, S. D., Page, A. J., ODonnell, T., & Blackshaw, L. A. (1997). Altered functional innervation of the ferret lower oesophageal sphincter (LOS) in oesophagitis.. GASTROENTEROLOGY, 112(4), A828. |
| 1995 | Smid, S., Frewin, D., Wyartt, C., & Head, R. (1995). Functional tolerance to a-adrenergic receptor blockade in the spontaneously hypertensive rat highlights the multi-functional role of vascular angiotensin II in the development of hypertension. Journal of Vascular Research, 32(4), 247-253. Scopus6 WoS6 Europe PMC4 |
| 1993 | Jonsson, J. R., Smid, S. D., Frewin, D. B., & Head, R. J. (1993). Angiotensin II-mediated facilitation of sympathetic neurotransmission in the spontaneously hypertensive rat is not associated with neuronal uptake of the peptide. Journal of Cardiovascular Pharmacology, 22(5), 750-753. Scopus17 WoS14 Europe PMC10 |
| Year | Citation |
|---|---|
| 2023 | Laws III, J. S., Shrestha, S., & Smid, S. D. (2023). Cannabis terpenes as neuroprotective agents: A focus on α-bisabolol. In V. R. Preedy, V. B. Patel, & C. R. Martin (Eds.), Medicinal Usage of Cannabis and Cannabinoids (pp. 207-215). Elsevier. DOI Scopus1 |
| 2014 | Das, S., & Smid, S. (2014). The Antiaggregative, Antiamyloid Properties of Bioactive Polyphenols in the Treatment of Alzheimer's Disease. In R. Watson (Ed.), Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy (pp. 73-76). United Kingdom: Academic Press. DOI Scopus2 |
| 2013 | Smid, S., & Musgrave, I. (2013). Dietary polyphenols as inhibitors of Β-amyloid-evoked neurotoxicity: implications for the treatment of Alzheimer's disease. In J. Sun, K. Prasad, A. Ismail, B. Yang, X. You, & L. Li (Eds.), Polyphenols: Chemistry, Dietary Sources and Health Benefits (1 ed., pp. 521-538). United States: Nova Science Publishers. |
| 2009 | Smid, S. (2009). Neuronal mechanosensitivity in the gastrointestinal tract. In A. Kamkin, I. Kiseleva, N. Tavernarakis, & P. Persson (Eds.), Mechanosensitivity of the nervous system (pp. 87-106). Russia: Springer. DOI |
| Year | Citation |
|---|---|
| 2023 | Smid, S., Shrestha, S., Choi, J. -S., & Zhang, W. (2023). Innate immunomodulatory actions of macroalgal phlorotannins: In vitro modulation of intestinal barrier function and epithelial ACE-2 expression. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 818-819). WILEY. |
| 2015 | Smid, S., Das, S., Musgrave, I., & Pukala, T. (2015). Bioactive polyphenol interactions with β amyloid: a comparison of binding, fibril inhibition and neuroprotection. In JOURNAL OF NEUROCHEMISTRY Vol. 134 (pp. 363-364). Cairns, AUSTRALIA: WILEY-BLACKWELL. |
| 2002 | Smith, A., & Smid, S. D. (2002). Effects of inflammatory bowel disease on human colonic neuromuscular function <i>in vitro</i>.. In GASTROENTEROLOGY Vol. 122 (pp. A319). W B SAUNDERS CO. |
| 2002 | Smid, S. D., & Blackshaw, L. A. (2002). Histamine 3 receptors inhibit vagal afferent mechanoreceptors in the ferret proximal stomach.. In GASTROENTEROLOGY Vol. 122 (pp. A140). W B SAUNDERS CO. |
| 1991 | HEAD, R. J., SMID, S. D., MANO, M., JONSSON, J. R., & FREWIN, D. B. (1991). CAPTOPRIL TREATMENT REVERSES THE ENHANCED CONCENTRATION OF 3-METHYLHISTIDINE IN RESISTANCE AND CONDUCTING VESSELS IN THE SPONTANEOUSLY HYPERTENSIVE RAT. In M. J. MULVANY, N. C. B. NYBORG, C. AALKJAER, S. STRANDGAARD, & A. M. HEAGERTY (Eds.), RESISTANCE ARTERIES, STRUCTURE AND FUNCTION Vol. 974 (pp. 325-328). DENMARK, REBILD: ELSEVIER SCIENCE PUBL B V. |
Grants and Funding
Research Support and Scholarship
| 2024 | Principal Investigator. Investigating the mechanisms of vaping associated lung injury from medicinal cannabis. MAWA Trust Research Grant | $AUD 20,000 |
| 2022 | Principal Investigator. Marine-derived bioactives and nutraceuticals: Sustainable use of marine products for health and wellbeing. AC21 Special Project Funding | $USD 15,000 |
| 2021 | Co-Investigator. Exploring the use of personalised CBD/THC dosing to prevent common and impactful symptoms of treatment in advanced cancer. The CANnabinoids for CANcer Therapy (CANCAN) Clinical Trial: Medical Research Futures Fund, Department of Health, Australian Goverment. | $AUD $1.5M |
| 2019 | Principal Investigator. Australia Japan Foundation Award, Dept Foreign Affairs and Trade. Enabling technologies in Personalised and Precision Medicine. | $AUD 38,600 |
| 2018 | JSPS Invitational Fellowship, Nagoya University. Development of Super-efficient Screening Technologies for Neural Cell Regulatory Products. |
¥JPY 342,000 |
| 2018 | Principal Investigator. Faculty Research Infrastructure Award. The University of Adelaide. | AUD $17,000 |
| 2017-18 | Principal Investigator. Faculty Research Development Award (with Prof Kato, Nagoya University and Dr Ian Musgrave). Novel neuroprotective agents targeting beta amyloid. The University of Adelaide. | AUD $15,500 |
| 2013-15 | Co-Investigator (with Ian Musgrave, Louise O’Keefe and Tara Pukala). 'Structure function relationships of anti-amyloid drugs: verification in an in-vivo model.' lnterdisciplinary Research Fund Grant, The University of Adelaide. | AUD $21,000 |
| 2011-13 | Principal Investigator. (Associate Investigator: Dr Rachel Gibson). Validation of an ex vivo human colonic mucosal explant colitis model. MAWA Trust Research Grant. | AUD $28,122 |
| 2010-12 | Principal Investigator Broad Medical Research Program, United States (IBD-0268R). Functional Expression of the Endocannabinoid System in Inflammatory Bowel Disease. | USD $130,000 |
Teaching and Course Coordination
| 2006-present | The University of Adelaide: Course Coordinator - PHARM 3102 Drug Discovery & Development; HLTH SC 2100 Fundamentals of Human Nutrition. Courses taught: Pharmacology 2100/2200 (Level 2 B.Hlth.Sci, B. Pharm. Eng.). Pharmacology for Nursing (Level 1&2, Bachelor of Nursing). PHARM 3101, 3102, 3103, HLTH SC 2100, 2103, 2104, 3100. Higher Degree by Research: Discipline Coordinator |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2024 | Principal Supervisor | In vitro neuroprotective effects of alpha-1 adrenoceptor antagonists | Doctor of Philosophy | Doctorate | Full Time | Mr Aari Jasper Oliphant-Hand |
| 2024 | Principal Supervisor | In vitro neuroprotective effects of alpha-1 adrenoceptor antagonists | Doctor of Philosophy | Doctorate | Full Time | Mr Aari Jasper Oliphant-Hand |
| 2022 | Co-Supervisor | Diagnosis and therapeutics of intrinsically disordered protein misfolding disorders | Doctor of Philosophy | Doctorate | Full Time | Mr Zohaib Raza |
| 2022 | Co-Supervisor | Diagnosis and therapeutics of intrinsically disordered protein misfolding disorders | Doctor of Philosophy | Doctorate | Full Time | Mr Zohaib Raza |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2022 - 2025 | Principal Supervisor | The bioactivity of cannabis phytochemicals for antimicrobial activity, gastrointestinal and urological protection | Doctor of Philosophy | Doctorate | Full Time | Mr Luke Thomas Wooley |
| 2022 - 2024 | Principal Supervisor | Characterizing the Neurological Bioactivity of Cannabis Phytochemicals | Doctor of Philosophy | Doctorate | Full Time | Mr John Laws III |
| 2019 - 2022 | Principal Supervisor | Characterising the Protective Bioactivity of Macroalgal Polyphenols | Doctor of Philosophy | Doctorate | Full Time | Mr Srijan Shrestha |
| 2017 - 2022 | Principal Supervisor | Exploring the Bioactivity and Therapeutic Potential of Structurally Diverse Phytochemicals in Neurodegenerative and Gastrointestinal Disease | Doctor of Philosophy | Doctorate | Full Time | Mr Dylan Thomas Marsh |
| 2016 - 2020 | Co-Supervisor | Visualising Intestinal Inflammation and Fibrosis using Zirconium-89 Labelled Antibodies in a Preclinical Model of Inflammatory Bowel Disease | Doctor of Philosophy | Doctorate | Full Time | Miss Nicole Dmochowska |
| 2015 - 2018 | Principal Supervisor | Small molecular inhibitors of Amyloid beta and alpha Synuclein amyloidogenic aggregation, toxicity and in silico design of amyloid-binding ligands | Doctor of Philosophy | Doctorate | Full Time | Mrs Sukanya Das |
| 2010 - 2014 | Principal Supervisor | The Effect of Cannabinoids on Cytokine Evoked Human Colonic Mucosal Damage and Caco-2 Epithelial Permeability | Doctor of Philosophy | Doctorate | Full Time | Mr Benjamin Harvey |
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 2015 - ongoing | Advisory Board Member | Scientific Advisory Board | LeafCann Pty Ltd | Australia |
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2009 - ongoing | Member | Scientific Organising Committee, Annual National Symposia: Urogenital and Gastrointestinal Research | - | - |
| Date | Role | Membership | Country |
|---|---|---|---|
| 2017 - ongoing | Member | Australia New Zealand Marine Biotechnology Society | Australia |
| 2016 - ongoing | Member | International Cannabinoid Research Society | - |
| 2014 - ongoing | Member | International Society for Neurochemistry | - |
| 2014 - ongoing | - | International Society for Neurochemistry | - |
| 2006 - ongoing | - | International Cannabinoid Research Society | - |
| 1991 - ongoing | Member | Australasian Society for Clinical and Experimental Pharmacology and Toxicology | - |
| 1991 - ongoing | - | Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT). | - |
| Date | Institution | Department | Organisation Type | Country |
|---|---|---|---|---|
| 2015 - ongoing | LeafCann Australia Pty Ltd | - | - | - |
| Date | Role | Editorial Board Name | Institution | Country |
|---|---|---|---|---|
| 2013 - ongoing | Board Member | Clinical and Experimental Physiology and Pharmacology Journal | - | - |
| 2012 - ongoing | Editor | CEPP journal | - | - |
| Date | Engagement Type | Partner Name |
|---|---|---|
| 2016 - ongoing | Consultant | CSIRO Materials Division |
Connect With Me
External Profiles
